Ratings for Quest Diagnostics ( DGX ) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $178.33, a high estimate of $185.00, and a low estimate of $172.00. This current average has increased by 7.04% from the previous average price target of $166.60.

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how financial experts perceive Quest Diagnostics ( DGX ) is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics ( DGX ). This information provides a snapshot of how analysts perceive the current state of the company.

Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics ( DGX ) compared to the broader market.

Price Targets: Gaining insights, analysts provide estimates for the future value of Quest Diagnostics's ( DGX ) stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's ( DGX ) market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Quest Diagnostics ( DGX ) analyst ratings.

All You Need to Know About Quest Diagnostics

Quest Diagnostics ( DGX ) is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Key Indicators: Quest Diagnostics's Financial Health

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Quest Diagnostics ( DGX ) displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.41%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Quest Diagnostics's ( DGX ) net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.04% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Quest Diagnostics's ( DGX ) ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.35% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Quest Diagnostics's ( DGX ) ROA excels beyond industry benchmarks, reaching 1.5%. This signifies efficient management of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 1.02, Quest Diagnostics ( DGX ) adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Significance of Analyst Ratings Explained

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.